Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/30786
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHerraiz, Celia-
dc.contributor.authorJiménez-Cervantes, Celia-
dc.contributor.authorSanchez-Laorden, Berta-
dc.contributor.authorGarcía-Borrón, José C.-
dc.date.accessioned2024-01-26T22:21:08Z-
dc.date.available2024-01-26T22:21:08Z-
dc.date.created2017-07-01-
dc.identifier.citationSeminars in Cell & Developmental Biology. Vol.78, June 2018, Pages 73-84es_ES
dc.identifier.issn1096-3634-
dc.identifier.issn1084-9521-
dc.identifier.urihttps://hdl.handle.net/11000/30786-
dc.description.abstractMelanoma, the most aggressive form of skin cancer, results from the malignant transformation of melanocytes located in the basement membrane separating the epidermal and dermal skin compartments. Cutaneous melanoma is often initiated by solar ultraviolet radiation (UVR)-induced mutations. Melanocytes intimately interact with keratinocytes, which provide growth factors and melanocortin peptides acting as paracrine regulators of proliferation and differentiation. Keratinocyte-derived melanocortins activate melanocortin-1 receptor (MC1R) to protect melanocytes from the carcinogenic effect of UVR. Accordingly, MC1R is a major determinant of susceptibility to melanoma. Despite extensive phenotypic heterogeneity and high mutation loads, the molecular basis of melanomagenesis and the molecules mediating the crosstalk between melanoma and stromal cells are relatively well understood. Mutations of intracellular effectors of receptor tyrosine kinase (RTK) signalling, notably NRAS and BRAF, are major driver events more frequent than mutations in RTKs. Nevertheless, melanomas often display aberrant signalling from RTKs such as KIT, ERRB1-4, FGFR, MET and PDGFR, which contribute to disease progression and resistance to targeted therapies. Progress has also been made to unravel the role of the tumour secretome in preparing the metastatic niche. However, key aspects of the melanoma-stroma interplay, such as the molecular determinants of dormancy, remain poorly understood.es_ES
dc.formatapplication/pdfes_ES
dc.format.extent12es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsinfo:eu-repo/semantics/closedAccesses_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectMelanomaes_ES
dc.subjectMelanocortin-1 receptores_ES
dc.subjectReceptor tyrosine kinase signallinges_ES
dc.subjectMelanoma progressiones_ES
dc.subjectResistance to targeted therapieses_ES
dc.subjectTherapy-induced secretomees_ES
dc.titleFunctional interplay between secreted ligands and receptors in melanomaes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.contributor.instituteInstitutos de la UMH::Instituto de Neurocienciases_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.semcdb.2017.06.021es_ES
Appears in Collections:
Instituto de Neurociencias


no-thumbnailView/Open:

 Functional interplay between secreted ligands and receptors in melanoma.pdf



1,9 MB
Adobe PDF
Share:


Creative Commons ???jsp.display-item.text9???